Patient characteristics (n=72)
| Characteristics | LCNEC | SCLC |
| Subjects | 28 (39%) | 44 (61%) |
| Sex | ||
| Male | 18 (64.3%) | 28 (63.6%) |
| Female | 10 (35.7%) | 16 (36.4%) |
| Age years | 65 (40–78) | 64 (46–80) |
| ECOG performance status | ||
| 0 | 15 (53.6%) | 34 (54.5%) |
| 1 | 9 (32.1%) | 12 (27.3%) |
| 2 | 4 (14.3%) | 8 (18.2%) |
| Smoking history | ||
| Never smoker# | 4 (14.3%) | 4 (9.1%) |
| Ever smoker | 24 (85.7%) | 40 (90.9%) |
| Clinical stage at first-line therapy | ||
| III | 10 (35.7%) | |
| IV | 18 (64.3%) | |
| Clinical stage at diagnosis | ||
| I–II | 6 (21.4%) | 2 (4.5%) |
| IIIA/IIIB | 7 (25%) | 14 (31.9%) |
| IV | 15 (53.6%) | 28 (63.6%) |
| Site of disease | ||
| Intrathoracic | 13 (46.4%) | 24 (54.5%) |
| Extrathoracic | 15 (53.6%) | 20 (45.5%) |
| Brain metastasis at diagnosis | ||
| Yes | 2 (7.1%) | 4 (90.9%) |
| No | 26 (92.9%) | 40 (9.1%) |
| Surgery at diagnosis | ||
| Yes | 6 (21.4%) | 2 (4.5%) |
| No | 22 (78.6%) | 42 (95.5%) |
| Type of surgery | ||
| Atypical resection | 1 (3.6%) | 0 (0%) |
| Lobectomy | 3 (10.7%) | 2 (4.5%) |
| Lobectomy+lymphadenectomy | 2 (7.1%) | 0 (0%) |
| Chemotherapy treatment | ||
| Cycles received | 6 (3–8) | 6 (3–8) |
| Consolidative TRT | ||
| Yes | 10 (35.7%) | 16 (36.4%) |
| No | 18 (64.3%) | 28 (63.6%) |
| PCI | ||
| Yes | 4 (14.3%) | 17 (38.6%) |
| No | 24 (85.7%) | 27 (61.4%) |
| Successive lines of chemotherapy | ||
| None | 14 (50%) | 16 (36.4%) |
| II | 12 (42.9%) | 21 (47.7%) |
| III | 2 (7.1%) | 7 (15.9%) |
Data are presented as n (%) or median (range). LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung cancer; TRT: thoracic radiotherapy; PCI: prophylactic cranial irradiation. #: <100 cigarettes in lifetime.